tetano
Editor, Senior Moderator
Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16801. [Epub ahead of print]
Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies.
Mart?n-Moro F[SUP]1[/SUP], Marquet J[SUP]1[/SUP], Piris M[SUP]1[/SUP], Michael BM[SUP]1[/SUP], S?ez AJ[SUP]1[/SUP], Corona M[SUP]1[/SUP], Jim?nez C[SUP]1[/SUP], Astibia B[SUP]1[/SUP], Garc?a I[SUP]1[/SUP], Rodr?guez E[SUP]2[/SUP], Garc?a-Hoz C[SUP]2[/SUP], Fort?n-Abete J[SUP]3[/SUP], Herrera P[SUP]1[/SUP], L?pez-Jim?nez J[SUP]1[/SUP].
Author information
Abstract
The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020).
This article is protected by copyright. All rights reserved.
PMID:32379921DOI:10.1111/bjh.16801
Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies.
Mart?n-Moro F[SUP]1[/SUP], Marquet J[SUP]1[/SUP], Piris M[SUP]1[/SUP], Michael BM[SUP]1[/SUP], S?ez AJ[SUP]1[/SUP], Corona M[SUP]1[/SUP], Jim?nez C[SUP]1[/SUP], Astibia B[SUP]1[/SUP], Garc?a I[SUP]1[/SUP], Rodr?guez E[SUP]2[/SUP], Garc?a-Hoz C[SUP]2[/SUP], Fort?n-Abete J[SUP]3[/SUP], Herrera P[SUP]1[/SUP], L?pez-Jim?nez J[SUP]1[/SUP].
Author information
Abstract
The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020).
This article is protected by copyright. All rights reserved.
PMID:32379921DOI:10.1111/bjh.16801